

**Remarks**

Applicants gratefully acknowledge the Examiner's Notice of Allowability.


Claims 22-47 are allowed. By this amendment, Applicants have amended claim 22 to correct a typographic error. Specifically, Applicants have added a closing parenthesis after "methyl)amino)carbonyl)-L-valinyl)amino." Applicants have also amended the paragraph beginning at page 1, line 23, of the specification to correct the same typographic error.

In addition, Applicants have amended claims 33, 36, 37 and 38 to correct typographic errors by replacing the term "compound" with "composition."

Furthermore, Applicants have amended the paragraph beginning at page 1, line 7, of the specification, to replace the phrase "is a conversion of the provisional filings" with "claims the benefit of U.S. provisional applications." Applicants respectfully submit that the use of the term "conversion" is an obvious mistake, particularly in view of the unsigned Declaration and Power Attorney filed May 22, 2000 and the signed Declaration and Power Attorney filed October 11, 2000, both of which state that the present application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60/137,634, filed June 4, 1999, and U.S. Provisional Application No. 60/177,020, filed January 9, 2000. Copies of these Declaration and Power Attorney are attached herewith as Exhibits A and B, respectively. The originally filed Fee Transmittal (without the conversion fee set forth in § 1.17(i)) and the official filing receipt also indicate that the use of the term "conversion" is an obvious mistake. A copy of each of these documents are attached herewith as Exhibits C and D, respectively.

Applicants respectfully submit that the above amendments to the specification and claims do not introduce new matter. Accordingly, entry of these amendments is respectfully requested. Although Applicants believe that no fee is due, the Commissioner is hereby authorized to charge any payment deficiency to deposit account number 01-0025 referring to docket number 6499.US.O2. Should the Examiner have any questions regarding this matter, the Examiner is invited to contact Applicants' representative designated below.

Respectfully submitted,

  
\_\_\_\_\_  
Xu Zhang  
Lim. Rec. No. L0116

Date: September 29, 2006

ABBOTT LABORATORIES  
Telephone: (847) 935-1133  
Facsimile: (847) 938-2623